You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
The company is commercializing a genome-wide sequencing method called MRDetect, developed by researchers at the New York Genome Center and Weill Cornell Medicine.
In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.
With $2.5 million in initial philanthropy funding, the consortium plans to launch several research projects and establish a data commons for storing and sharing results.
The screening platform, which uses the Cas13 nuclease to target RNA instead of DNA, can be used to design guide RNAs for CRISPR research.
Unlike the Hi-C chromosome conformation assay, the Pore-C technique reveals information that's lost with short-read sequencing.
A new study in Science used allele-specific expression data to find candidate genes that may have contributed to mendelian muscle disease in patients.
The method allows for the annotation of cells by their genotype and capture of single-cell transcriptomes, even when the cells aren't morphologically distinct.
A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.